Enact Holdings Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Enact Holdings Inc (ACT) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Enact Holdings Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 1,254M vs 502,704M combined for tracked competitors (0.2% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (+1.3% annualized vs trailing 12 months), vs accelerating (+4.1%) for its tracked peer group.
- Growth: Enact Holdings Inc generated 4.1% revenue growth year over year in Q2 2026, vs 11.5% for its tracked competitors combined.
- Profitability: Its 55.1% net margin compares with 17.1% for the peer group.
- Scale: Enact Holdings Inc ranks #10 of 30 companies by market capitalization in the Insurance Brokerage industry, holding 2.0% of industry market cap.
- Peer revenue share: Enact Holdings Inc accounted for 0.2% of combined revenue among its tracked peer group, down from 0.3% a year earlier.
- Peer differentiation: Revenue per employee of $2.99M compares with $0.87M for the peer group (3.5x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ACT Sales vs. its Competitors, Q2 2026
Enact Holdings Inc reported revenue growth of 4.07 % year on year in Q2 2026, below its competitors' combined revenue growth of 11.50 %.
With a net margin of 55.10 %, Enact Holdings Inc achieved higher profitability than its competitors (17.05 %).
Enact Holdings Inc generated 0.24 % of the combined sales of its peer group, down from 0.26 % a year earlier.
Enact Holdings Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Enact Holdings Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Enact Holdings Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (2) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Enact Holdings Inc's competitor groups requires a Commercial License.
For context: the Insurance Brokerage industry grew revenue 10.7% year over year, combined, vs 4.1% for Enact Holdings Inc. Enact Holdings Inc's share of combined industry revenue moved from 0.84% to 0.79%, a loss of 0.05 percentage points.
Enact Holdings Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Enact Holdings Inc | Yes | Yes | No | - |
| Competitors combined (19) | ||||
| High-Confidence Competitors (2) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ACT Stock Performance relative to its Competitors
ACT Stock Performance relative to High-Confidence Competitors
ACT Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Merck and Co Inc | 282.9% | Outperformed |
| 2 | Eli Lilly And Company | 282.9% | Outperformed |
| 3 | Amgen Inc | 282.9% | Outperformed |
| 4 | Johnson and Johnson | 282.9% | Outperformed |
| 5 | Financial Institutions Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Enact Holdings Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Enact Holdings Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Enact Holdings Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Enact Holdings Inc | 6,586.39 | 1,253.54 |
| Eli Lilly And Company | 1,058,837.89 | 79,665.80 |
| Johnson and Johnson | 663,585.20 | 97,929.00 |
| Abbvie Inc | 471,581.88 | 64,386.00 |
| Merck and Co Inc | 367,264.30 | 66,569.00 |
| Amgen Inc | 227,462.72 | 38,095.00 |
| SUBTOTAL | 3,380,231.73 | 549,091.69 |
Sign in to see all competitors of Enact Holdings Inc .
Sources: Enact Holdings Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Enact Holdings Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Enact Holdings Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Nmi Holdings Inc | Named by the company | 85% |
| Genworth Financial Inc | Named by the company | 85% |
| Financial Institutions Inc | Named by the company | 85% |
| First Bancorp | Named by the company | 85% |
| First Bancorp | Named by the company | 85% |
| Mgic Investment Corp | Named by the company | 85% |
| Fair Isaac Corp | Named by the company | 85% |
| Essent Group Ltd | Named by the company | 85% |
| Arch Capital Group Ltd | Named by the company | 85% |
| Radian Group Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Enact Holdings Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Enact Holdings Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.26 % |
| Merck and Co Inc | Pharmaceutical segment 88.88 % |
| Amgen Inc | Reportable 100.00 % |
| Abbott Laboratories | Diabetes Care 17.78 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Enact Holdings Inc .
Enact Holdings Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Enact Holdings Inc | 6,586 | 2,991,737 | 1,630,711 |
| Eli Lilly And Company | 1,058,838 | 1,593,316 | 534,224 |
| Johnson and Johnson | 663,585 | 695,518 | 149,411 |
| Abbvie Inc | 471,582 | 1,129,579 | 110,807 |
| Merck and Co Inc | 367,264 | 887,587 | 42,267 |
| Amgen Inc | 227,463 | 2,930,385 | 672,538 |
| PEERS TOTAL | 3,373,645 | 866,127 | 149,395 |
Sign in to see all peers for Enact Holdings Inc .
Enact Holdings Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 61.21 % |
| Johnson and Johnson | United States 57.42 % |
| Merck and Co Inc | EMEA 23.60 % |
| Abbott Laboratories | Non-US 61.62 % |
| Pfizer Inc | United States 58.91 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Enact Holdings Inc .
Enact Holdings Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 29 companies in Enact Holdings Inc's industry classification, broader than the peer set above. Market cap in millions of $.Enact Holdings Inc ranks #10 of 29 companies by market capitalization in its industry, holding 1.99 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,516, indicating a moderately concentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Marsh and Mclennan Companies Inc | 81,472 | 25.67 % |
| 2 | Arthur J Gallagher and Co | 58,902 | 18.56 % |
| 3 | Aon Plc | 58,202 | 18.34 % |
| 4 | Willis Towers Watson Plc | 27,458 | 8.65 % |
| 5 | Brown and Brown Inc | 1,234 | 5.2% |
| 6 | Equitable Holdings Inc | 1,234 | 5.2% |
| 7 | Erie Indemnity Company | 1,234 | 5.2% |
| 8 | Fidelity National Financial Inc | 1,234 | 5.2% |
| 9 | First American Financial Corporation | 1,234 | 5.2% |
| 10 | Enact Holdings Inc | 6,311 | 1.99 % |
Market cap and industry share for the rest of Enact Holdings Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-06-26.
Enact Holdings Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 5 | Brown and Brown Inc | 20,120 | -34.95 % |
| 6 | Equitable Holdings Inc | 14,558 | 3.12 % |
| 7 | Erie Indemnity Company | 11,606 | -29.95 % |
| 8 | Fidelity National Financial Inc | 10,968 | -25.74 % |
| 9 | First American Financial Corporation | 1,234 | 12.3% |
| 10 | Enact Holdings Inc | 6,311 | 22.38 % |
| 11 | Ryan Specialty Holdings Inc | 1,234 | 12.3% |
| 12 | Corvel Corporation | 1,234 | 12.3% |
| 13 | The Baldwin Insurance Group Inc | 1,234 | 12.3% |
| 14 | Ethos Technologies Inc | 1,234 | 12.3% |
| 15 | Stewart Information Services Corp | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Enact Holdings Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Enact Holdings Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Insurance Brokerage industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (18 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | - | 56.03 % (avg) | - |
| Operating Margin | - | industry median | - |
| EBITDA Margin | 72.23 % | 1.85 % (avg) | +70.4 pp |
| Capital Intensity (Capex / Revenue) | 0.00 % | 1.24 % (avg) | -1.2 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Enact Holdings Inc's Valuation vs Competitive Position
Valuation multiples vs the Insurance Brokerage industry average (18 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 9.3x | 13.3x | -4.0x |
| EV / EBITDA | 5.8x | 12.6x | -6.9x |
| P/B | 1.2x | 2.7x | -1.6x |
| Return on Equity | 12.76 % | industry aggregate | -2.87 % |
| Return on Invested Capital | - | 8.14 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Enact Holdings Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -31.97 % | -87.68 % | 5.36 % | 4.17 % | 2.83 % |
| Operating Margin | 8.40 % | 62.13 % | 64.02 % | 63.66 % | 46.64 % |
| Return on Invested Capital | 0.88 % | 7.13 % | 7.08 % | 6.75 % | 5.01 % |
| P/E | 20.6x | 5.7x | 6.8x | 7.7x | 8.7x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Enact Holdings Inc's BCG Growth-Share Matrix
Relative market share (vs Enact Holdings Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Enact Holdings Inc falls in the Dog quadrant: relative market share of 0.08x vs its largest competitor, in an industry growing revenue 6.7% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Enact Holdings Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Moderate | Industry HHI of 1,516 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 1.24 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Enact Holdings Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Enact Holdings Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Enact Holdings Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Enact Holdings Inc falls in the Medium attractiveness / Medium strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Enact Holdings Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Low relative market share vs the industry leader (0.08x).
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Enact Holdings Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Enact Holdings Inc | - | - | 0.14 |
| Eli Lilly And Company | 0.20 | 1.48 | 1.59 |
| Johnson and Johnson | 0.37 | 1.05 | 0.60 |
| Abbvie Inc | 0.16 | 0.75 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
Sign in to see all peers for Enact Holdings Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Enact Holdings Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Enact Holdings Inc | Q2 2026 | +4.1 % | +4.2 % |
| Eli Lilly And Company | Q2 2026 | +47.7 % | +25.3 % |
| Johnson and Johnson | Q2 2026 | +6.6 % | -0.1 % |
| Abbvie Inc | Q2 2026 | +10.2 % | +284.3 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| PEERS TOTAL | +11.2 % | -7.2 % |
Sign in to see all peers for Enact Holdings Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Enact Holdings Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Enact Holdings Inc | Q2 2026 | - | - |
| Eli Lilly And Company | Q2 2026 | +33.5 % | +72.8 % |
| Johnson and Johnson | Q2 2026 | +5.5 % | +26.7 % |
| Abbvie Inc | Q2 2026 | -1.3 % | +19.7 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
Sign in to see all peers for Enact Holdings Inc .
Enact Holdings Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Enact Holdings Inc | 9.87% | 10.78% | 12.76% |
| Eli Lilly And Company | 21.97% | 33.95% | 92.54% |
| Johnson and Johnson | 10.60% | 13.30% | 25.74% |
| Abbvie Inc | 4.68% | 9.11% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
Sign in to see all peers for Enact Holdings Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Enact Holdings Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Enact Holdings Inc | 9.94 | 5.25 |
| Eli Lilly And Company | 39.77 | 13.29 |
| Johnson and Johnson | 31.48 | 6.78 |
| Abbvie Inc | 75.22 | 7.32 |
| Merck and Co Inc | 119.91 | 5.52 |
| Amgen Inc | 25.97 | 5.97 |
| PEERS AVERAGE | 35.51 | 6.16 |
Sign in to see all peers for Enact Holdings Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.